Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma that requires treatment~* No prior systemic treatment within 4 weeks of enrollment~* No corticosteroids within 2 weeks prior to study entry~* Measurable disease must be present~* No concomitant anti-cancer therapies~* ECOG status \</= 2~* Patients with HIV infection are eligible~* Patients with treated CLL or SLL in CNS are eligible~* Non-pregnant and non-nursing~* Life expectancy greater than 60 days~* Adequate bone marrow, kidney and liver function~* No major surgery within 28 days or minor surgery within 5 days of starting treatment~Exclusion Criteria:~* History od Richter's transformation~* History of prior allogeneic transplant~* Radioimmunotherapy within 1 year of enrollment~* Prior Bruton's tyrosine kinase inhibitor or lenalidomide~* History of allergic reactions to compounds similar to ibrutinib, lenalidomide or rituximab or hypersensitivity~* active or uncontrolled autoimmune hemolytic anemia or ITP~* Transfusion-dependent thrombocytopenia or bleeding disorders~* Active hepatitis B or C infections~* History of known Human Anti-Chimeric Antibody positivity~* History of erythema multiforme, toxic epidermal necrolysis, or Stevens-Johnson syndrome~* History of uncontrolled seizures~* Autoimmune disorder that requires active immunosuppression~* Stroke or intracranial hemorrhage within last 6 months~* History of congestive heart failure, myocardial infarction, unstable angina, uncontrolled arrhythmia or any Class 3 or 4 heart disease in the last 6 months~* No prior malignancy except if treated with curative intent with no active disease for more than 3 years; adequately treated non-melanoma skin cancer or cervical cancer in situ~* using warfarin or similar Vitamin K antagonists Unable to swallow capsules or disease significantly affecting gastrointestinal function or inhibiting small intestine absorption

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide, Ibrutinib, Rituximab (Type: EXPERIMENTAL): Rituximab on day 1, lenalidomide days 1-21 and ibrutinib continuously for 6 cycles or until disease progression or intolerance to the combination. Single agent ibrutinib will then be continued until disease progression or intolerance.

Based on this trial design, predict the completion outcome and termination type (if applicable).